Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: Clinical features, treatment, and results in trials NHL-BFM 86 and 90

Sampaio

et al. 2015

Rev. Assoc. Med. Bras.

Section: Discussioncontrasting

confidence: 52%

Section: Discussionmentioning

confidence: 50%

See 1 more Smart Citation

Outcome of children and adolescents with lymphoblastic lymphoma

Sampaio

et al. 2015

Rev. Assoc. Med. Bras.

“…It is related closely to acute lymphoblastic leukemia (ALL), from which it can be differentiated by the predominant extramedullary involvement in LL and bone marrow infiltration by blast cells of less than 25% [1,2]. In adults, LL is treated with regimens that are used to treat ALL (ALL-type regimens) [3][4][5][6][7][8][9], but these regimens give inferior results compared with those achieved normally in children [10][11][12]. One relevant issue is the role of mediastinal tumors in the failure of treatment, and debate persists as to whether all patients should undergo mediastinal irradiation or only those with residual disease post-induction.…”

Section: Introductionmentioning

confidence: 99%

Results of a lymphoblastic leukemia-like chemotherapy program with risk-adapted mediastinal irradiation and stem cell transplantation for adult patients with lymphoblastic lymphoma

et al. 2011

The therapeutic role of mediastinal radiotherapy and stem cell transplantation (SCT) in lymphoblastic lymphoma (LL) remains controversial. In a risk-oriented design, we adopted a flexible treatment program in which (1) patients with persistent mediastinal abnormality, evaluated by post-induction computed chest tomography, received mediastinal irradiation; and (2) those with persistence of minimal residual disease (MRD), evaluated by MRD analysis of the bone marrow, underwent SCT.Twenty-eight out of 30 patients (T-lineage, n=24; Blineage, n=6) achieved a complete response. Of 21 patients with mediastinal mass, 13 (62%) achieved a complete response after chemotherapy alone, while 6 (28.5%) required additional irradiation. Eleven patients were evaluated for MRD: 6 were negative and 5 positive. On the basis of MRD findings and clinical risk characteristics, 14 patients underwent SCT, 13 received maintenance chemotherapy, and 1 had local radiotherapy. Five patients Sergio Cortelazzo and Renato Bassan contributed equally to the manuscript.Electronic supplementary material The online version of this article

“…In the Berlin Frankfurt Munster (BFM) study group, for example, B-LBL cases were treated using ALL-type protocol with a total therapy duration of at least 24 months. 17 In contrast, mature B-cell lymphoma cases, including Burkitt lymphoma and diffuse large B-cell lymphoma, are treated using a short course of treatment that is usually completed within a year. 18 Each type of Blineage lymphoma is morphologically unique and distinctive upon histological examination.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic importance of CD179a/b as markers of precursor B-cell lymphoblastic lymphoma

et al. 2004

Surrogate light chains consisting of VpreB (CD179a) and k5 (CD179b) are expressed in precursor B cells lacking a complete form of immunoglobulin and are thought to act as substitutes for conventional light chains. Upon differentiation to immature and mature B cells, CD179a/b disappear and are replaced with conventional light chains. Thus, these molecules may be useful as essential markers of precursor B cells. To examine the expression of the surrogate light-chain components CD179a and CD179b in precursor B-cell lymphoblastic lymphoma, we analyzed tissue sections using immunohistochemistry techniques. Among a number of monoclonal antibodies for the surrogate light chains, VpreB8 and SL11 were found to detect CD179a and CD179b, respectively, in acetone-fixed fresh frozen sections. Moreover, we also observed VpreB8 staining in formalin-fixed, paraffin-embedded sections. Using these antibodies, we found that CD179a/b were specifically expressed in precursor B-cell lymphoblastic lymphomas, but not in mature B-cell lymphomas in childhood. Furthermore, other pediatric tumors that must be included in a differential diagnosis of precursor B-cell lymphoblastic lymphoma, including precursor T-cell lymphoblastic lymphoma, extramedullary myeloid tumors, and Ewing sarcoma, were also negative for both CD179a and CD179b. Our data indicate that CD179a and CD179b may be important markers for the immunophenotypic diagnosis of precursor B-cell lymphoblastic lymphomas.